基蛋生物收盘上涨1.36%，滚动市盈率20.57倍，总市值41.54亿元

Company Overview - Company name is 基蛋生物科技股份有限公司, primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company is recognized as a key high-tech enterprise under the National Torch Program and is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector [1] Financial Performance - As of the latest quarterly report for Q1 2025, the company achieved revenue of 244 million yuan, representing a year-on-year decrease of 24.08% [1] - The net profit for the same period was 64.31 million yuan, down 25.24% year-on-year, with a sales gross margin of 77.15% [1] Market Position - The company's stock closed at 8.19 yuan, with a PE ratio of 20.57 times, while the average PE ratio for the medical device industry is 49.64 times [1][2] - The total market capitalization of the company is 4.154 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]